PhaseBio Pharmaceuticals EBIT

The latest EBIT for PHAS is $26M as of June 2022. That compares with $-110M in the prior-year period — up 124.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside PhaseBio Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHAS's EBIT moved from $-110M to $26M — a 124.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PhaseBio Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, PHAS currently prints $26M for EBIT, while the sector average sits near $23B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at PhaseBio Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $26M for PHAS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting PHAS's EBIT ($26M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.